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Gene targeting: Applications in transplantation research. Gene ing the manipulation of individual nucleotides [3], dupli-
targeting, the manipulation of gene in the mouse genome using cation of the target locus with its associated regulatory
homologous recombination in embryonic stem cells, is a power- regions [4], and alteration in the gene in only specificful experimental tool that has been widely utilized in a number
tissues [5].of disciplines. The ability to precisely alter genes in this way
The ability to alter genes precisely in this way has hadprovides an avenue for investigating the role of a gene product
in normal and pathological processes in the intact animal, with immense utility in a number of areas. In particular, these
a precision and efficacy not possible using pharmacological technologies have provided an avenue for applying the
agents, antibodies or engineered proteins. In transplant re- power of molecular genetics to studies in whole animalsearch, gene targeting provides a unique tool for discriminating
systems. Thus, knockout mice can be used to determinethe contributions of gene expression in donor versus recipient
the role of a gene product in normal and pathologicaltissues. This review focuses on several areas in transplantation
research where gene targeting has made useful contributions. processes in intact animals with a precision and efficacy
These include studies of the role of donor and recipient multi- that is not possible using pharmacological agents, anti-
ple histocompatibility complex antigens in regulating rejection bodies, or engineered proteins. These techniques mayresponses, the role of CD41 T cell in mediating acute rejection,
be especially useful for identifying the role of an individ-and the functions of cytokines during rejection and tolerance
ual gene product in complex responses in vivo, such asinduction. These studies highlight the unique advantages of
gene targeting in studies of complex processes in whole animals the reaction that occurs when foreign tissue is trans-
and illustrate the contributions of this technique to understand- planted into a genetically disparate host [6, 7]. Moreover,
ing the pathogenesis of allograft rejection. in transplantation research, gene targeting provides a
unique tool for separately identifying the contribution
of gene expression in donor versus recipient tissues by
Manipulation of genes in the mouse genome using using the genetically manipulated animal as either the
homologous recombination in embryonic stem cells transplant donor or recipient.
(“gene targeting”) is a powerful experimental tool that Because of these characteristics, there has been wide
has achieved widespread application in a number of sci- ranging use of gene targeting in transplantation research
entific disciplines [1, 2]. Using this technique, alterations to explore a variety of issues [8]. In this article, we review
of cloned DNA produced in a test tube are inserted at some of these applications while attempting to highlight
precise locations in the mouse genome, where they are unique contributions of gene targeting to these experi-
transmitted to subsequent generations as stable genetic ments. In some cases, knockout mice have confirmed
traits. In the majority of mouse lines that have been existing paradigms, whereas in other cases, they have
produced using these techniques, null mutations are cre- raised interesting new questions about the pathogenesis
ated in the targeted gene locus. These targeted gene of allograft rejection.
disruptions are termed “gene knockouts.” Although a
gene knockout is the simplest alteration that can be pro-
duced through gene targeting, other more complex GENE TARGETING STUDIES
changes in the target gene can be accomplished, includ- IN TRANSPLANTATION
Transplantation of organs in which expression of
major histocompatibility complex antigens has been
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Fig. 1. Schematic structure of major histo-
compatibility complex (MHC) class I and class
II antigens. MHC class I molecules are com-
posed of a polymorphic heavy chain composed
of three a domains. The heavy chain, which
is encoded within the MHC (K, L, or D in the
mouse) is noncovalently associated with b2-
microglobulin. The b2-microglobulin gene lies
on chromosome 2 outside the MHC locus.
MHC class II antigens are composed of a and
b chains, both of which are encoded within
the MHC locus.
event leads to T-cell activation and the generation of a Skin grafts from class I-deficient mice transplanted across
major and most minor MHC disparities were rapidlyvigorous immune response in which donor MHC pro-
teins become targets for cellular and humoral effector rejected [14]. Similarly, vigorous rejection of class II-
deficient skin grafts was also observed [15–17]. Remark-responses leading to graft injury and destruction. Among
the first knockout mice that were produced were animals ably, skin grafts devoid of both class I and class II were
also rejected rapidly [16, 18] through a T-cell–dependentin which the genes encoding components of MHC anti-
gens had been disrupted (Fig. 1). MHC class I-deficient mechanism.
Earlier cell culture studies had shown that Db class Imice were produced through targeted disruption of the
b2-microglobulin gene [9, 10]. This gene is located out- heavy chains could be detected on the surface of mutant
cell lines that lacked b2-microglobulin [19]. Whenside of the MHC, and it encodes the nonpolymorphic
component of the class I heterodimer. Because b2-micro- b2-microglobulin–deficient mice were produced, class I
Db heavy chains could also be detected on the surfacesglobulin is required for the normal assembly and cell-
surface expression of the class I antigen complex, of their lymphocytes [10, 20]. Moreover, using stimulator
cells from b2-microglobulin–deficient mice, it was dem-b2-microglobulin–deficient mice were grossly deficient in
their expression of all MHC class I antigens. As the onstrated that these class I heavy chains could prime
cytotoxic T-cell responses [20] even across minor histo-normal development of CD81 T cells requires a produc-
tive interaction between developing thymocytes and compatibility differences [21], suggesting that they could
function to present peptides to T cells. The presence ofMHC class I antigens in the thymus (positive selection),
b2-microglobulin–deficient mice are also grossly deficient class I heavy chains on the surface of thymic epithelium
was also sufficient to mediate positive selection of smallin CD81 T cells [9, 10]. This observation proved the
critical requirement of class I antigens in the positive numbers of CD81 T cells in b2-microglobulin–deficient
mice [22, 23]. Thus, in b2-microglobulin–deficient mice,selection of CD81 T cells. Class II-deficient mice were
produced by creating a null mutation in the Abb chain class I antigen expression is markedly reduced, but not
completely absent, and this “leaky” phenotype may pro-of the I-A molecule. In these mice, which are of the H-2b
genetic background, I-A is the only class II protein that vide an explanation for the rejection of combined class
I2/II2 skin grafts. Indeed, studies by Lee et al showedis expressed [11]. Thus, the destruction of the Abb gene
completely ablates class II antigen expression in these that rejection of MHC-deficient skin was mediated by
CD81 T cells that recognize free class I heavy chainsanimals. As MHC class II antigens are required for the
positive selection of CD41 T cells, the class II-deficient [24]. Accordingly, more effective strategies to eliminate
class I expression, such as targeted disruption of genesmice were grossly deficient in their complement of CD41
T cells [12, 13]. encoding individual class I heavy chains [25] or transcrip-
tion factors that regulate MHC expression [26], mayBecause the b2-microglobulin and Abb genes are lo-
cated on different chromosomes, these mutations could provide a more complete protection against rejection.
Compared with the results with skin grafts, the survivalbe combined by simple breeding, and mice that were
deficient in the expression of both classes of MHC anti- of vascularized organ grafts that lack MHC antigens was
generally prolonged. This probably reflects basic differ-gens were generated. It was hoped that this approach
might yield “universal donors” that could be trans- ences in the character and requirements for immune
responses to directly vascularized organ grafts comparedplanted across MHC disparities without inducing rejec-
tion. From this perspective, the initial experiments with with skin. For example, prolonged survival has been doc-
umented for donor class I2 [27, 28], class II2 [29], orskin grafts were somewhat surprising and disappointing.
Mannon and Coffman: Gene targeting20
combined class I2/II2 cardiac allografts [29]. The survival demonstrated in studies by Bix et al [33]. These investiga-
tors found that bone marrow transplants from MHCof class I2 liver allografts is also prolonged, even when
the recipient is presensitized [28]. However, in most cir- class I-deficient donor mice were rejected in a matter of
days, whereas the wild-type marrow survived indefi-cumstances, the MHC-deficient allografts are eventually
rejected. nitely. This robust rejection was shown to be mediated
by NK cells. A role for NK cells in rejection of MHC-In kidney allografts, we found that the glomerular
filtration rate (GFR) is preserved in allografts from do- deficient skin or vascularized organ allografts has not
been demonstrated. In our own studies, we can detectnors that are deficient in class I [30], class II (abstract;
Mannon et al, J Am Soc Nephrol 5:984, 1994), or both only very small numbers of cells bearing NK markers in
class I-deficient kidney grafts, and it seems unlikely thatclass I and II antigens (abstract; Mannon et al, J Am Soc
Nephrol 8:660A–661A, 1997). In the early period after they play any substantive role in the rejection of MHC-
deficient kidney grafts (Mannon et al, unpublished obser-transplantation, the degree of preservation of GFR was
similar whether the graft lacked a single or both classes vations).
of MHC antigens. Despite the improvement in GFR
Pathways for direct and indirect allorecognitioncompared with controls, the histomorphology of the
MHC-deficient kidney allografts is markedly abnormal Rejection is initiated through specific interactions be-
tween the T-cell receptor on recipient lymphocytes andand is characterized by substantial inflammatory cell in-
filtrates with tubulitis and vasculitis. However, there are MHC antigens derived from the donor. These recogni-
tion events serve to activate a specific population ofsome differences in the character of the intragraft im-
mune response in MHC-deficient grafts compared with T cells, leading to a vigorous immune response. The
recognition of alloantigens may occur through two dis-controls. For example, a reduced tempo for the accumu-
lation of CD81 T cells in the graft is seen in the class tinct pathways (Fig. 2) [reviewed in 34]. In the direct
recognition pathway (which is unique to alloimmune re-I-deficient transplants [31], whereas a dramatic reduction
in the number of CD41 T cells is seen in class II2 kidney sponses), recipient T cells interact directly with MHC
antigens on the surface of donor antigen-presenting cells.allografts compared with controls (abstract; Mannon et
al, J Am Soc Nephrol 5:984, 1994). In addition, antibodies In the indirect pathway, recipient T cells recognize pep-
tides derived from donor MHC proteins that have beenagainst donor class I antigens are not detected in serum
of recipients of class I2 [30] or class I2/II2 kidneys (ab- processed by recipient antigen presenting cells (APCs)
and are presented in the context of self MHC [reviewedstract; Mannon et al, J Am Soc Nephrol 8:660A–661A,
1997) compared with the elevated levels that are seen in 35]. This is the usual pathway used by the immune
system for processing and the presentation of nominalin controls. Thus, reduced levels of expression of donor
MHC antigens on kidney allografts ameliorate kidney antigens.
It has been suggested that these two pathways forinjury in acute rejection and can reduce the tempo of
accumulation of T cells in the graft. However, even in alloantigen presentation and recognition may play dis-
tinct roles in the pathogenesis of rejection. Accordingly,the absence of a normal expression of class I and II
proteins, a vigorous intragraft immune response occurs. the direct recognition pathway may be primarily respon-
sible for the intensity and high precursor frequency ofAlthough this may be triggered, in part, by the recogni-
tion of free class I heavy chains, the intensity of the alloimmune responses in acute rejection. The high pre-
cursor frequency of cells capable of direct recognitionreaction suggests a role for indirect alloantigen recogni-
tion (discussed later in this article) and/or for factors in of allo-MHC has been attributed to differences in density
of cell surface MHC molecules or the through recogni-the microenvironment of the graft that may regulate
the dimension and severity of the intragraft immune tion of alloreactive MHC molecules by “molecular mim-
icry” [reviewed in 34]. On the other hand, the repertoireresponse independent of cell surface MHC expression.
Although reduced expression of donor alloantigens for recognition of alloantigens through the indirect path-
way is much smaller [36, 37]. This indirect pathway maycan ameliorate rejection, the absence of donor MHC
antigens can, in some circumstances, be detrimental to be important in the pathogenesis of chronic rejection
[36, 38] and may be more resistant to conventional immu-graft survival because of lysis of MHC-deficient tissue
by natural killer (NK) cells from the host. NK cells are nosuppressive agents [39]. Although the relative roles of
direct and indirect allorecognition in transplant rejectionlarge lymphoid cells that possess receptors for MHC
class I proteins [reviewed in 32]. The engagement of are difficult to distinguish in vivo, the capacity to geneti-
cally manipulate MHC gene expression in mice has pro-these receptors by MHC class I proteins causes inhibition
of NK cell function. Thus, the absence MHC antigens vided an experimental approach to study the contribu-
tions of the distinct allorecognition pathways to grafton the surface of a cell may preferentially target these
cells for lysis by NK cells. The potential for NK cells to rejection.
The existence and initial characterization of the indi-mediate the rejection of MHC-deficient allografts was
Mannon and Coffman: Gene targeting 21
rect pathway for allorecognition were addressed in stud- the other hand, depleting recipients of CD41 T cells with
antibodies results in prolonged allograft survival [45, 46]ies by Auchincloss et al using class II-deficient mice [15].
They found that class II-deficient skin grafts were rapidly and, in some cases, donor-specific tolerance [47, 48]. The
interpretation of this work is complicated, however, byrejected by wild-type mice, and they hypothesized that
this rejection was mediated by recognition of MHC class limitations of the experimental approaches that were
used [reviewed in 49]. Although depleting antibody regi-I antigens by CD81 T cells. However, the administration
of anti-CD8 antibodies to the recipient did not prevent mens can be used effectively to reduce a particular cell
population, subpopulations of the target cells that retainrejection of class II-deficient grafts. In the animals that
received anti-CD8 antibody, a small population of resid- functional reactivity may persist [50]. Direct stimulation
of target cells by the antibody may be an additionalual CD81 cells could be detected, and these cells seemed
to be responsible for the rejection of the class II-deficient confounding factor. Finally, in adoptive transfer studies,
it may be difficult to completely eliminate contaminationallografts [17]. Furthermore, the cytolytic activity of
these cells required help from CD41 T cells that had of T-cell subpopulations that are purified by negative
selection.been sensitized to donor-derived peptides through the
indirect pathway for allorecognition. These experiments The generation of mice with targeted disruptions of
the CD4 or CD8 genes has proved useful in furtherprovided clear-cut evidence for the function of the indi-
rect allorecognition pathway in mediating allograft rejec- characterizing the cellular requirements for graft rejec-
tion without some of the problems inherent to antibodytion in vivo. Additional evidence for indirect allorecogni-
tion in skin graft rejection was demonstrated by these depletion or adoptive transfer studies. To address the
requirement for CD81 T cells during graft rejection,authors using class I2/II2 mice. As discussed earlier in
this article, wild-type mice efficiently reject skin allo- CD8-deficient (CD82/2) mice were transplanted with
MHC-disparate skin [51–53] and cardiac allografts [53].grafts from class I2/II2 donors [18]. In order to examine
the role of the indirect allorecognition pathway in the The CD8-deficient mouse lines lack CD81 T cells and
exhibit minimal cytotoxic T-lymphocyte (CTL) functionrejection of MHC-deficient grafts, class II-deficient mice
were bred with transgenic mice that express class II anti- against MHC class I [54]. Despite the lack of CTL func-
tion, both skin and heart allografts were rejected withgens only on thymic medullary epithelium [40]. The re-
sulting mice have normal numbers of CD41 T cells but the same tempo in CD82/2 mice as in wild-type recipi-
ents [52, 53]. Allografts were also rejected efficiently bylack class II antigens on their APCs; therefore, they are
unable to present donor alloantigens through the indirect mice lacking perforin [55–57] or granzyme B [58]. These
molecules serve as the molecular effectors for cytolyticpathway. These class II knockout/I-E transgenic mice
do not reject MHC-deficient skin grafts [24], suggesting activity of CD81 T cells [59]. Thus, experiments using
knockout mice suggest that CD81 T cells and the mole-that the rejection of MHC-deficient skin was accom-
plished through indirect allorecognition. cules that mediate their cytotoxic effects are not abso-
lutely required for allograft rejection.
Relative roles of CD41 and CD81 T cells in CD4 knockout mice have been used in a similar fash-
transplant rejection ion to address the role of CD41 T cells in rejection.
CD41 T cells are absent in CD4-deficient (CD42/2)The CD41 and CD81 populations of T cells specifically
recognize antigen in the context of MHC class II or mice, whereas the CD81 T-cell population appears to
be normal; T-helper responses in CD42/2 mice are alsoclass I, respectively, and properties of the CD4 and CD8
proteins are critical for these specific MHC interactions markedly reduced [60]. The survival of skin or cardiac
allografts that are transplanted into CD42/2 mice is[41]. These cell populations also serve different functions
in allograft rejection. Although their roles are not exclu- prolonged compared with controls [53]. When CD42/2
mice are reconstituted with purified CD41 T cells, rejec-sive, the CD41 population tends to exert “helper” func-
tions in coordinating the alloimmune response, whereas tion responses proceed as in wild-type mice. These stud-
ies further demonstrate the important role of CD41 TCD81 cells comprise the major effector population of
cytolytic cells. The relative requirements for CD41 and cells in allograft rejection.
CD81 T cells during allograft rejection have been studied
Role of cytokines in allograft rejectionextensively, and roles for both subpopulations are sup-
ported by past experiments [reviewed in 42]. For exam- When T cells are activated following alloantigen rec-
ognition, the alloimmune response is amplified andple, in the setting of an isolated MHC class I difference
between donor and recipient, rejection depends predom- shaped through the actions of soluble cytokines, which
promote T-cell growth and differentiation [reviewed ininantly on the CD81 T-cell response, as demonstrated
by adoptive transfer studies in which purified CD81 T 61]. There are several lines of evidence supporting a key
role for cytokines in the pathogenesis of rejection. Forcells caused rejection [43] or in studies in which the
depletion of CD81 T cells abrogated rejection [44]. On example, the expression of a wide range of cytokines is
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Fig. 2. Pathways of recognition of foreign an-
tigens. (A) Direct allorecognition. T cell re-
ceptors (TCR) on recipient T cells interact
directly with intact donor major histocompati-
bility complex (MHC) antigens on antigen
presenting cells (APCs) derived from the do-
nor organ (shaded circles). CD81 T cells pref-
erentially interact with MHC class I antigens,
whereas CD41 T cells recognize MHC class
II antigens. (B) Indirect allorecognition. Re-
cipient T cells recognize peptides derived from
donor MHC proteins that have been pro-
cessed by recipient APCs and are presented
in the context of self MHC expressed on APCs
from the recipient.
up-regulated within rejecting allografts compared with lymphotoxin. Th1 cells generally function to promote
cellular immune responses. In contrast, the Th2 pheno-nonrejecting isografts [62]. Moreover, the putative mech-
type is characterized by the production of IL-4, IL-5,anism of action of cyclosporine and FK-506 in sup-
IL-6, and IL-10 and is associated with the developmentpressing rejection is thought to be their potent ability to
of humoral immune responses, in particular those thatinhibit the transcription of cytokine genes [reviewed in
involve production of IgE.63]. However, it has been difficult to ascribe specific
Following transplantation, it has been suggested thatfunctional roles for individual cytokines in allograft re-
a predominant Th1 response will promote rejection,jection.
whereas a Th2 response will favor the development ofIn addition to the effects of cytokines to promote
tolerance [reviewed in 66]. This hypothesis has beenT-cell proliferation, specific profiles of cytokine produc-
based primarily on circumstantial evidence showing pre-tion have been correlated with distinct T-cell functions.
dominant expression of Th1-type cytokines in rejecting
Such responses have been suggested to play a key role in grafts [62, 67, 68] and expression of Th2 cytokines within
a variety of immune responses [reviewed in 64], including allografts in tolerant hosts [69–71]. It has been difficult,
allograft rejection [reviewed in 65]. For CD41 cells, however, to directly test the functional relevance of this
which are the central regulatory cell in allograft rejection Th1/Th2 paradigm in allograft rejection. Recently, mice
(discussed earlier in this article), two major functional with targeted disruptions of cytokine genes have been
phenotypes have been described that are defined by spe- used to examine the roles of individual cytokines in allo-
cific patterns of cytokine production (Table 1). The Th1 graft rejection and to evaluate critically the relationship
phenotype is characterized by production of cytokines of Th1 and Th2 responses in the development of rejec-
tion and allograft tolerance.such as interleukin-2 (IL-2), interferon-g (IFN-g), and
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in allografts transplanted into IL-2–deficient allograft
recipients [73], suggesting that redundancy within the
cytokine network might be sufficient to support rejection
when IL-2 is absent.
Interferon-g is another Th1 cytokine that was consid-
ered essential for allograft rejection [62]. IFN-g activates
T cells and macrophages and has potent effects on MHC
antigen expression [74]. By virtue of its effects to pro-
mote T-cell differentiation toward the Th1 phenotype
[64], enhanced IFN-g production would be anticipated to
promote the development of cellular immune responses
that would lead to graft rejection. As with the IL-2–
deficient mice, transplantation experiments using mice
with targeted disruption of the IFN-g gene yielded un-
expected results. Allografts transplanted into IFN-g–
deficient recipients were rejected with a tempo and se-
verity equivalent to allografts in wild-type mice [75, 76].
Moreover, mRNAs for the Th2 cytokines IL-4 and
IL-10 were expressed at high levels in IFN-g–deficient
recipients [75]. These results clearly demonstrated that
IFN-g is not necessary for acute allograft rejection.
Taken together with results from the IL-2 knockout ex-
periments, it is clear that rejection can proceed in the
absence of prototypical Th1-type cytokines. In this set-
ting, predominant expression of Th2 cytokines is not
sufficient to prolong graft survival.
After experiments with knockout mice demonstrated
that Th1 cytokines were not necessary for allograft rejec-
tion, the converse experiments were done to determine
whether Th2 cytokines were required to induce allograft
tolerance. In these experiments, mice lacking IL-4 were
used. IL-4 is required for the normal development and
differentiation of Th2 cells, and IL-4–deficient mice are
unable to mount Th2 immune responses [77]. Islet [78]
and cardiac allografts [79] were rapidly rejected in IL-
4–deficient mice. In wild-type mice, blocking the B7-CD28
Fig. 2. Continued. and CD40-CD40 ligand pathways for T-cell costimula-
tion leads to long-term allograft survival and, in some
cases, donor-specific tolerance [80]. This treatment also
effectively induces long-term survival of islet [78] andInterleukin-2 is a Th1 cytokine that has been consid-
ered to have fundamental importance in the pathogene- cardiac allografts [79] transplanted into IL-4 2/2 mice.
Thus, prolonged allograft survival can be induced in thesis of transplant rejection. The inhibition of IL-2 produc-
tion has been suggested to underlie the efficacy of absence of IL-4, and immune deviation toward a Th2
pattern is not required to achieve long-term graft survivalcyclosporine and FK-506, two pharmacological agents
that are extremely effective in preventing allograft rejec- in these animals.
More recent experiments by Lakkis et al have exam-tion [63]. Thus, it was quite surprising when Steiger et
al reported that islet allografts were rapidly rejected by ined whether or not the absence of Th1 cytokines facili-
tates the development of allograft tolerance [79]. In theseIL-2 knockout mice and that the character and histologi-
cal pattern of rejection in IL-2–deficient mice were virtu- studies, costimulatory blockade with CTLA4-Ig and
antigp39 antibodies induced long-term survival of car-ally identical to controls [72]. However, despite their
ability to reject islet transplants, IL-2–deficient mice diac allografts in wild-type mice, but not in IFN-g (2/2)
recipients [81]. The treatment with neutralizing anti–failed to generate CTL activity in vitro, and their re-
sponses to mitogens were impaired unless exogenous IFN-g antibodies also abrogated the ability of costimula-
tory blockade to improve graft survival. Thus, these ex-IL-2, IL-4, or IL-7 were provided [72]. Expression of
IL-15, another potent T-cell growth factor, was enhanced periments using knockout mice clearly show that the
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Table 1. Principal subsets of mouse CD41 T cells
Th1 Th2
Cytokines secreted IL-2, IFN-g, lymphotoxin IL-4, -5, -6, -9, -10
TNF-a, GM-CSF, IL-3 TNF-a, GM-CSF, IL-3
Immune functions Macrophage activation B cell activation
Delayed-type hypersensitivity Mast cell and eosinophil production
Antibody dependent cell-mediated cytotoxicity Antibody production
Transplant response ??Promotes rejection ??Supports tolerance
absence of a quintessential Th1 cytokine does not facili- are due to the absence of the targeted gene product from
tate long-term graft survival. Furthermore, they have developmental defects or compensatory effects related
suggested an unexpected requirement of IFN-g for the to the absence of the gene product through embryogene-
development of allograft tolerance. sis. For example, it has been suggested that the rejection
In summary, studies using cytokine-knockout mice of allografts in IL-2–deficient mice may be mediated by
suggest that the pathogenesis of allograft rejection and up-regulation of other cytokine genes, such as IL-15 [73].
tolerance cannot be strictly explained through the Th1/ These compensatory effects might not occur in the nor-
Th2 paradigm. The complexity of the response is further mal immune system, and therefore, these studies may
illustrated by studies of cytokine expression in human underestimate the contribution of IL-2 in allograft rejec-
transplant biopsies showing simultaneous expression of tion. Although an absolute distinction between these
both Th1 and Th2 cytokines in rejecting grafts [82, 83]. possibilities may be quite difficult to achieve, combining
gene targeting with other experimental interventions canIssues in the interpretation of gene
be helpful. This approach has been used by Lakkis et altargeting experiments
in their studies exploring the role of IFN-g in toleranceDuring the course of this review, we have emphasized
induction (discussed earlier in this article) [79, 81]. Thesethe many positive attributes of gene targeting as a tool
investigators found that the genetic absence of IFN-gfor studying transplantation biology. However, as with
and neutralizing antibodies against IFN-g had similarany other approach, there are factors that need to be
effects in interfering with the ability of costimulatoryconsidered when interpreting experiments that employ
blockade to induce tolerance. Similar results using twothis technology. One is the potential influence of back-
complementary interventions provide a compelling argu-ground genes on phenotype. Most knockout mice are
ment that the inability to induce tolerance is due to theproduced using embryonic stem cells derived from mice
absence of IFN-g and not due to generalized abnormali-of the 129 strain. Because 129 mice are poor breeders
with low fecundity, chimeras and their progeny bearing ties in the immune system caused by the absence of
the targeted mutation are often bred and expanded using IFN-g during fetal development.
other inbred lines, such as C57BL/6. Mice that are gener- Many of the experiments using gene targeting to study
ated in this way will possess a random and heterogeneous transplantation have used homozygous knockout ani-
mix of background genes. In transplantation experi- mals, with complete deficiencies of the target gene. This
ments, these background genes will determine the array provides an attractive experimental approach for under-
of major and minor histocompatibility antigens that are standing the role of a particular gene product in rejection.
expressed and may influence the character of the recipi- In the human population, there may be genetic variations
ent’s immune responses. These potentially confounding that incrementally alter the function of a gene. For exam-
effects can be minimized by using mice that bear the ple, polymorphisms in the genes for the cytokines tumor
mutation on inbred backgrounds. Such animals can be
necrosis factor-a and IL-10 may alter the production of
obtained through repeated backcrossing that may re-
these cytokines, and these polymorphisms have beenquire 12 to 18 months to generate. Alternatively, the
suggested to affect the character of allograft rejectionmutation can be maintained on a 129 background from
[86]. The effects of this type of mutation on graft rejec-the beginning stages of breeding, keeping in mind that
tion could also be explored, using, for example, micethis will increase the time necessary to generate adequate
that are heterozygous (1/2) for a targeted mutation.numbers of animals for experiments. As an additional
These animals often exhibit approximately an 50% re-solution to this dilemma, several new embryonic stem
duction in total expression of the target gene. Alterna-cell lines derived from non-129 inbred mouse lines have
tively, in animals with duplication of the target gene, thebeen developed recently [84, 85].
role of enhanced expression of a particular gene productWhen performing studies with knockout mice, it is
also important to distinguish physiological events that might be examined.
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